Study of targeted therapy before surgery for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have non-small cell lung cancer (NSCLC) that can be removed by surgery (stages IB to IIIB).
- Your tumor must have a specific KRAS G12C mutation, confirmed by a genetic test.
- You cannot have had any previous treatment for this lung cancer (like chemo, radiation, or targeted therapy).
- You must be in good general health (able to care for yourself and do light activities) and have no major health issues affecting your organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (Fulzerasib and Ivonescimab) as a first treatment for advanced or metastatic lung cancer that has a specific KRAS G12C mutation. The goal is to see if this treatment works well and is safe.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.